Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Abstract Text:

Audrey Rousseau,Catherine L Nutt,Rebecca A Betensky,A John Iafrate,Moonjoo Han,Keith L Ligon,David H Rowitch,David N Louis,

The phenotypic heterogeneity of astrocytic and oligodendroglial tumor cells complicates establishing accurate diagnostic criteria, and lineage-specific markers would facilitate diagnosis of glioma subtypes. Based on data from the literature and from expression microarrays, we selected molecules relevant to gliogenesis and glial lineage specificity and then used immunohistochemistry to assess expression of these molecules in 55 diffuse gliomas, including 8 biphasic oligoastrocytomas, 21 oligodendrogliomas (all with 1p/19qloss), 21 astrocytomas, and 5 glioblastomas. For the astrocytic lineage markers (GFAP, YKL-40, and ApoE), GFAP expression was significantly higher in the astrocytic component of oligoastrocytomas compared with the oligodendroglial part; similar patterns were detected for YKL-40 and ApoE, although the differences were not significant. GFAP, YKL-40, and ApoE reliably distinguished grade II-III oligodendrogliomas from grade II-IV astrocytomas (p < 0.0001, p = 0.002, and p < 0.0001, respectively). Among the oligodendroglial lineage markers (Olig2, Sox10, ASCL1, and NKX2-2), ASCL1 and NKX2-2 displayed significantly different immunostaining between oligodendrogliomas and astrocytomas (p = 0.017 and 0.004, respectively), but none clearly differentiated between the 2 glial populations of oligoastrocytomas. In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Publishing Authors By Initials

A Rousseau,CL Nutt,RA Betensky,AJ Iafrate,M Han,KL Ligon,DH Rowitch,DN Louis,

For similar biological factors: biological markers: tumor markers, biological research abstracts see: biological factors: biological markers: tumor markers, biological research

PUBMED ID PMID:

MEDLINE DATE:

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: Journal of neuropathology and experimental neurolo

VOLUME: 65

Page Numbers: 1149-56

Journal Abbreviation: J. Neuropathol. Exp. Neurol.

ISSN: 0022-3069

DAY: 3

MONTH: Dec

YEAR: 2006

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2985192

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Keywords Mesh Terms:

KEYWORDS: Tumor Markers, Biological

MESH TERMS: metabolism

Chemical & Substance for Abstract: Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. Information

Substance Name: apolipoprotein E1

Registry Number: 0

Grant and Affiliation Information for Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.

AFFILIATION: Molecular Pathology Unit, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

Country: United States

AGENCY: United States NCI

GRANT: CA 95616

ACRONYM: CA

MEDLINETA: J Neuropathol Exp Neurol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2 Related Publications

• Anatomical ontologies of mosquitoes and ticks, and their web browsers in VectorBase.
• Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level.
• Comment on "Superficial palmar communications between the ulnar and median nerves in Turkish cadavers".
• Different epitopes of the LACK protein are recognized by V beta 4 V alpha 8 CD4+ T cells in H-2b and H-2d mice susceptible to Leishmania major.
• Downregulation of RUNX3 and TES by hypermethylation in glioblastoma.
• Essential tremor.
• Essential tremor: emerging views of a common disorder.
• Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2.
• Gestational age and gestational age-at-delivery: cause, effect, or time-scale?
• Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate.
• Initial approach to the child who presents in presumed septic shock.
• Intracellular calcium regulation of connexin43.
• Kinetic tremor: differences between smokers and non-smokers.
• Localization of telomeres and telomere-associated proteins in telomerase-negative Saccharomyces cerevisiae.
• Mechanisms involved in the cerebrovascular dilator effects of N-methyl-d-aspartate in cerebral cortex.
• Mediterranean diet and essential tremor. A case-control study.
• Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.
• Molecular pathology of malignant gliomas.
• Neurologic Manifestations ofWhipple's Disease.
• PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer.
• Plasma renin and angiotensin levels in human hypertension following treatment.
• Plasma renin, urinary sodium excretion and vascular disease.
• Prevalence of taurodontism in premolars among patients at a tertiary care institution in Trinidad.
• Reflux disease and Barrett's esophagus.
• Risk and opportunity in upgrading the US drinking water infrastructure system.
• Silas Weir Mitchell's essential tremor.
• Variation in quality of diabetes care at the levels of patient, physician, and clinic.
• [Innovative therapies in inflammatory bowel disease at the CHU]
• [Lung cancer. Epidemiology and etiologic factors]
• [Not Available.]